HKSTP
13.1.2023 13:25:39 CET | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) has partnered with world-leading innovation platform, Plug and Play, to call on ambitious startups and entrepreneurs around the world to join the seventh Elevator Pitch Competition 2023 (EPiC 2023), one of the biggest pitch events in Hong Kong. The final entry deadline for the Competition has also been extended to 20 January 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005179/en/
HKSTP CEO, Albert Wong, joins Plug and Play CEO, Saeed Amidi, to promote HKSTP’s EPiC 2023, calling all startups in the world to come to Hong Kong for a scale-up opportunity of a lifetime. (Photo: Business Wire)
This offers local and global startups the chance to join the combined HKSTP and Plug and Play eco-systems to launch their potential innovations onto the global stage. Interested parties on two technology tracks (FinTech and PropTech) only need to submit a 2-min video introduction to make a potentially life-changing decision. 50 shortlisted semi-finalists will have the golden opportunity to be considered by HKSTP Venture Fund for direct investment of up to US$5 million as well as market expansion support in Asia and beyond, plus the chance to win a cash prize of US$60,000 if crowned champion.
As the world’s leading accelerator, Plug and Play will leverage its global network to organise international competitions in Asia, Europe and Northern America throughout February to bring in overseas startups to the April final in Hong Kong.
Hong Kong provides the ideal platform to expand into the vast Asian market, being a gateway to both Mainland China and Asia. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
Albert Wong, CEO of HKSTP, said: “This year, our flagship event EPiC is set to be the biggest and best-ever as we partner with world-renowned Plug and Play, elevating the investment platform to a truly global level. This collaboration cements HKSTP and Hong Kong as a unique global launchpad to rapidly scale up innovators on their growth journey, while achieving our mission to propel success and advance Hong Kong's I&T development.”
Saeed Amidi, CEO of Plug and Play, said: “Partnering with HKSTP on EPiC is a major step forward in our mission to harness the huge Asia opportunity to build the world’s leading innovation platform. We are partnering with changemakers like HKSTP to build a unique innovation ecosystem by connecting the brightest minds with world-leading corporations, VC firms, universities, and government agencies across multiple industries.’’
EPiC 2023 will take place at the iconic sky100 venue atop Hong Kong’s tallest building, International Commerce Centre, to create a genuine elevator pitch experience for startups.
Who can apply:
- Tech startups that are less than 10 years old
- Ideas should focus on one of the TWO technology tracks: FinTech and PropTech
Applications will close on 20 January 2023 at 23:59 (Hong Kong time).
Please visit the website (https://epic.hkstp.org/) for more information on EPiC 2023.
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
About Plug and Play
Plug and Play was established in Sunnyvale, California - a region within the renowned Silicon Valley. Although officially founded in 2006, the early stages of the business could be traced back to 1998. The company contains business functions, including tech investment, corporate innovation, and innovation space. Plug and Play now has 50 regional offices in over 30 countries and regions worldwide. With nearly 20 years of experience in early-stage tech investment, Plug and Play has successfully invested in and incubated numerous big tech companies, including PayPal, Google, Dropbox, LendingClub, Guardant Health, Rappi, N26, Honey, etc. It has invested in over 1,500 startups and accelerated over 17,000 programs globally. Each year, Plug and Play provides open innovation services for over 500 world-leading corporations through over 1,000 matchmaking activities with cutting-edge technology companies.
Formally established in 2016, Plug and Play China currently has 3 regional innovation hubs in Beijing (China HQ), Shanghai (Plug and Play Innovation Hub - Yangtze River Delta Area), and Shenzhen (Shenzhen Innovation Center). Plug and Play China also provides open innovation services in Nanjing, Wuhan, Wuxi etc.
There are 4 main business functions across Plug and Play China’s innovation platform including corporate innovation, city innovation, tech investment, and innovation space.
It has built China's leading international innovation ecosystem and created a multi-dimensional open innovation platform that includes corporations, startups, universities and research labs, government agencies, venture capitalist firms, and city innovation partners.
Since 2016, Plug and Play China has engaged with 100+ industry-leading corporations, accelerated over 1700 startups, and has invested in over 150 startups including ApplyBoard, AutoX, Flexiv, ZiFiSense, ROBOTICPLUS.AI, INGEEK, Hexaflake, Authing, Yours, etc.
Please visit www.pnpchina.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005179/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom